274 related articles for article (PubMed ID: 34209034)
1. Influence of Different Glycoproteins and of the Virion Core on SERINC5 Antiviral Activity.
Diehl WE; Guney MH; Vanzo T; Kyawe PP; White JM; Pizzato M; Luban J
Viruses; 2021 Jun; 13(7):. PubMed ID: 34209034
[TBL] [Abstract][Full Text] [Related]
2. Functional Interplay Between Murine Leukemia Virus Glycogag, Serinc5, and Surface Glycoprotein Governs Virus Entry, with Opposite Effects on Gammaretroviral and Ebolavirus Glycoproteins.
Ahi YS; Zhang S; Thappeta Y; Denman A; Feizpour A; Gummuluru S; Reinhard B; Muriaux D; Fivash MJ; Rein A
mBio; 2016 Nov; 7(6):. PubMed ID: 27879338
[TBL] [Abstract][Full Text] [Related]
3. SERINC5 Potently Restricts Retrovirus Infection
Timilsina U; Umthong S; Lynch B; Stablewski A; Stavrou S
mBio; 2020 Jul; 11(4):. PubMed ID: 32665269
[TBL] [Abstract][Full Text] [Related]
4. IFITM3 Reduces Retroviral Envelope Abundance and Function and Is Counteracted by glycoGag.
Ahi YS; Yimer D; Shi G; Majdoul S; Rahman K; Rein A; Compton AA
mBio; 2020 Jan; 11(1):. PubMed ID: 31964738
[TBL] [Abstract][Full Text] [Related]
5. Aromatic Side Chain at Position 412 of SERINC5 Exerts Restriction Activity toward HIV-1 and Other Retroviruses.
Tan TS; Toyoda M; Tokunaga K; Ueno T
J Virol; 2021 Aug; 95(18):e0063421. PubMed ID: 34190600
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation.
Rosa A; Chande A; Ziglio S; De Sanctis V; Bertorelli R; Goh SL; McCauley SM; Nowosielska A; Antonarakis SE; Luban J; Santoni FA; Pizzato M
Nature; 2015 Oct; 526(7572):212-7. PubMed ID: 26416734
[TBL] [Abstract][Full Text] [Related]
7. A Conserved Acidic-Cluster Motif in SERINC5 Confers Partial Resistance to Antagonism by HIV-1 Nef.
Stoneham CA; Ramirez PW; Singh R; Suarez M; Debray A; Lim C; Jia X; Xiong Y; Guatelli J
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941773
[TBL] [Abstract][Full Text] [Related]
8. Intracellular trafficking of Gag and Env proteins and their interactions modulate pseudotyping of retroviruses.
Sandrin V; Muriaux D; Darlix JL; Cosset FL
J Virol; 2004 Jul; 78(13):7153-64. PubMed ID: 15194792
[TBL] [Abstract][Full Text] [Related]
9. The Antagonism of HIV-1 Nef to SERINC5 Particle Infectivity Restriction Involves the Counteraction of Virion-Associated Pools of the Restriction Factor.
Trautz B; Pierini V; Wombacher R; Stolp B; Chase AJ; Pizzato M; Fackler OT
J Virol; 2016 Dec; 90(23):10915-10927. PubMed ID: 27681140
[TBL] [Abstract][Full Text] [Related]
10. Sequence Determinants in Gammaretroviral Env Cytoplasmic Tails Dictate Virus-Specific Pseudotyping Compatibility.
Song YE; Olinger GY; Janaka SK; Johnson MC
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894464
[TBL] [Abstract][Full Text] [Related]
11. Multiple Gag domains contribute to selective recruitment of murine leukemia virus (MLV) Env to MLV virions.
Gregory DA; Lyddon TD; Johnson MC
J Virol; 2013 Feb; 87(3):1518-27. PubMed ID: 23152533
[TBL] [Abstract][Full Text] [Related]
12. SERINC5 Can Enhance Proinflammatory Cytokine Production by Primary Human Myeloid Cells in Response to Challenge with HIV-1 Particles.
Pierini V; Gallucci L; Stürzel CM; Kirchhoff F; Fackler OT
J Virol; 2021 Apr; 95(9):. PubMed ID: 33597208
[TBL] [Abstract][Full Text] [Related]
13. Murine Leukemia Virus Glycosylated Gag Reduces Murine SERINC5 Protein Expression at Steady-State Levels via the Endosome/Lysosome Pathway to Counteract SERINC5 Antiretroviral Activity.
Li S; Ahmad I; Shi J; Wang B; Yu C; Zhang L; Zheng YH
J Virol; 2019 Jan; 93(2):. PubMed ID: 30355687
[TBL] [Abstract][Full Text] [Related]
14. Effect of HIV-1 Env on SERINC5 Antagonism.
Beitari S; Ding S; Pan Q; Finzi A; Liang C
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928004
[TBL] [Abstract][Full Text] [Related]
15. The retroviral accessory proteins S2, Nef, and glycoMA use similar mechanisms for antagonizing the host restriction factor SERINC5.
Ahmad I; Li S; Li R; Chai Q; Zhang L; Wang B; Yu C; Zheng YH
J Biol Chem; 2019 Apr; 294(17):7013-7024. PubMed ID: 30862674
[TBL] [Abstract][Full Text] [Related]
16. S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.
Chande A; Cuccurullo EC; Rosa A; Ziglio S; Carpenter S; Pizzato M
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13197-13202. PubMed ID: 27803322
[TBL] [Abstract][Full Text] [Related]
17. SERINC5 restricts influenza virus infectivity.
Zhao F; Xu F; Liu X; Hu Y; Wei L; Fan Z; Wang L; Huang Y; Mei S; Guo L; Yang L; Cen S; Wang J; Liang C; Guo F
PLoS Pathog; 2022 Oct; 18(10):e1010907. PubMed ID: 36223419
[TBL] [Abstract][Full Text] [Related]
18. An N-Glycosylated Form of SERINC5 Is Specifically Incorporated into HIV-1 Virions.
Sharma S; Lewinski MK; Guatelli J
J Virol; 2018 Nov; 92(22):. PubMed ID: 30158294
[TBL] [Abstract][Full Text] [Related]
19. The Antiviral Factor SERINC5 Impairs the Expression of Non-Self-DNA.
Shi Y; Simpson S; Ahmed SK; Chen Y; Tavakoli-Tameh A; Janaka SK; Evans DT; Serra-Moreno R
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766367
[TBL] [Abstract][Full Text] [Related]
20. Potent Enhancement of HIV-1 Replication by Nef in the Absence of SERINC3 and SERINC5.
Wu Y; Olety B; Weiss ER; Popova E; Yamanaka H; Göttlinger H
mBio; 2019 Jun; 10(3):. PubMed ID: 31186327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
